Real-world clinical effectiveness and exploratory longitudinal immunological changes of Efgartigimod in myasthenia gravis: a retrospective study and a single-cell analysis in one patient
The clinical cohort findings support the effectiveness and favorable safety profile of Efgartigimod in routine practice, and exploratory single-cell and immune repertoire analyses from one patient provide preliminary insights into potential immunological changes beyond IgG reduction.